PubMed Health⌕ Search

Biomedical subjects

C L Olweny

Publications and source records attributed to C L Olweny.

At least 19 recordsLinked to original sources
PubMed1992

Non-haematological toxicity limiting the application of sequential high dose chemotherapy in patients with advanced breast cancer.

A programme of repeated high dose chemotherapy for advanced breast cancer was developed using (1) cyclophosphamide 4 g/m2 followed by autologous peripheral blood stem cell (PBSC) collection; (2) three cycles of conventional dose chemotherapy; (3) high dose cyclophosphamide, cisplatin, and carmustine with PBSC rescue; and (4) high dose etoposide and melphalan with PBSC rescue. Fifteen eligible patients had advanced poor prognosis breast cancer either at initial diagnosis (one patient) or at relapse (14 patients). During the course of the protocol, there were three treatment related deaths, two patient withdrawals due to debilitating toxicity, five patient withdrawals due to disease progression, and one patient withdrawal due to inadequate collection of PBSC. The remaining four patients did not complete the planned protocol as the programme was terminated because of the unacceptable morbidity and mortality. They were treated with an alternative high dose chemotherapy protocol which was well tolerated. This study highlights the significant problems associated with a complex sequential high dose chemotherapy regimen. Cyclophosphamide mobilized PBSC infused following high dose chemotherapy enables rapid haematological recovery. However the non-haematological toxicity following high dose chemotherapy regimens is often severe and may limit the application of certain sequential high dose chemotherapy combinations in patients with breast cancer.

Adult↗
PubMed1991

Goals and rationale of cancer treatment.

OBJECTIVE: To provide an overview of the goals and rationale for cancer management. DATA SOURCES: Primarily the series "Changing concepts in the management of cancer" published in the Journal between December 1987 and September 1990 (see Box). STUDY SELECTION: Tumour types chosen for the series of articles were those with a high incidence, such as melanoma and tumours of the lung, breast and prostate, or curable tumours, such as acute leukaemias and lymphomas. DATA SYNTHESIS: Emphasis is placed on primary prevention, with lung cancer related to smoking as a model. Breast cancer serves as a model for secondary prevention and adjuvant therapy. The role of goal setting as the first step in cancer treatment is stressed. Some of the reasons why cure is now possible are discussed, as are criteria for the selection of tumours for adjuvant therapy and indications for starting palliative treatment. CONCLUSIONS: Cancer cure is no longer a myth but a reality. To overcome present barriers to the cure of some cancers, there is need for a better understanding of the biology of epithelial solid tumours including the mechanisms to overcome multiple drug resistance. The restoration of functional health after cure is attained is paramount. Quality of life as a measure of success should be included in all clinical trials.

Goals↗
PubMed1991

Primary central nervous system lymphoma. A report of 9 cases and review of the literature.

Primary central nervous system (CNS) lymphoma appears to be on the increase. This increase is real rather than due to changes in nosology, physician awareness or increase in high-risk groups. Diagnostic guidelines appear to be well defined and widely accepted. We report 9 cases of primary CNS lymphoma seen at our institution over a 5-year period. The clinical presentation was variable, but consisted mostly of headache, motor dysfunction, and memory and behavioural disturbance. Surgery is of value for diagnosis. In general, surgical decompression is not recommended. Glucocorticoids and radiotherapy appear effective in the short term. The role of chemotherapy is uncertain.

Adult↗
PubMed1989

Treatment of malignancy-associated hypercalcemia with norethisterone: a case report.

Hypercalcemia is a common cause of morbidity in cancer patients. The mechanism of malignancy-associated hypercalcemia includes increased bone resorption and decreased renal calcium clearance which also occur in primary hyperparathyroidism. Norethisterone can inhibit bone resorption and has recently been shown to be effective treatment for mild hyperparathyroidism in post menopausal women. We report the successful use for the first time of norethisterone (5 mg daily) in a case of malignancy-associated hypercalcemia after other standard agents failed.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1989

Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerations.

The disposition of unchanged cisplatin was compared after two- and 24-hour intravenous (IV) infusion to eight patients with germ cell cancer (dose, 100 mg/m2), 14 patients with head and neck cancer (dose, seven patients 50 mg/m2; seven patients, 100 mg/m2). Patients were randomized to receive either a two- or 24-hour infusion in the first course of treatment and the reverse in the second course. Cisplatin renal clearance, total clearance, and the percentage of the dose excreted unchanged in urine were significantly lower with the longer infusion. Total clearance was 345 +/- 97.0 mL/min/m2 after the two-hour infusion and 268 +/- 70.7 mL/min/m2 after the 24-hour infusion (P less than .0001). Renal clearance was 79.1 +/- 35.3 mL/min/m2 and 34.1 +/- 14.9 mL/min/m2 (P less than .0001). The percentage of the dose excreted unchanged in urine was 22.9 +/- 6.5% and 12.8 +/- 4.0%, respectively (P less than .0001). The ratio of cisplatin renal clearance to creatinine clearance was 1.95 +/- .96 after the two-hour infusion and .90 +/- .40 after the 24-hour infusion (P less than .001). There was only a poor relationship between cisplatin renal clearance and creatinine clearance after a two-hour infusion (r2 = .05, P greater than .1) or 24-hour infusion (r2 = .18, P greater than .05). The severity of emesis was graded on a four-point scale and was significantly less with the 24-hour infusion than with the two-hour infusion (P less than .05). Twenty-four-hour infusion of cisplatin resulted in greater drug retention in patients due to reduced renal clearance, but was also associated with reduced emetic toxicity, probably as a result of lower peak plasma levels.

Adolescent↗
PubMed1986

Typhoid colitis.

Explore the source record for details and available documents.

Adult↗
PubMed1986

Adult cerebral malaria in Zambia: preliminary report of clinical findings and treatment response.

Fifty-six adult patients diagnosed as having 'cerebral malaria' were admitted and treated over a 4 month period. The presenting symptoms were similar to those of control patients with malaria without cerebral manifestations except that vomiting and convulsions were significantly more frequent and joint pains were less frequent in the cases than in the controls. Physical examination revealed significantly more frequent occurrence of nuchal rigidity, positive Kernig's sign, confusion, muteness, pallor and jaundice in the cases than controls, while splenomegaly was significantly more common in controls than cases. Laboratory data showed that cerebral malaria cases had significantly lower haemoglobin and significantly higher reticulocyte count and erythrocyte sedimentation rate than controls. There was no significant difference in the parasite density between the cases and controls. All patients were treated with 200 mg base of intravenous chloroquine in 250 ml of isotonic saline infused over 2 h and repeated 12 hourly till oral therapy was possible. This proved to be efficacious and the recovery rate was over 90%. Five patients died and the diagnosis was confirmed in three in whom autopsy was permitted. A simple staging system is proposed which retrospectively seems to have prognostic value. It is recommended that the validity of this system be tested prospectively.

Adolescent↗
PubMed1985

Treatment of Burkitt's lymphoma: the African experience.

Although Burkitt's lymphoma (BL) can be treated by surgery, radiotherapy and immunotherapy, chemotherapy is the mainstay of treatment. This paper summarizes the various clinical trials undertaken in Africa over the past decade. The single most effective drug for BL is cyclophosphamide (CPM). Given alone for remission induction, CPM is as effective as combinations consisting of either CPM, vincristine (VCR) and methotrexate (MTX) or CPM, VCR and cytosine arabinoside (Ara-C). Survival data indicate that single-dose CPM is comparable to multiple doses. Thus, maintenance therapy may not be necessary, and may in fact worsen the final outcome. Intrathecal (IT) MTX given together with systemic therapy significantly delays central nervous system (CNS) relapse, which is not prevented by cerebrospinal irradiation. For established CNS disease, IT-Ara-C for three days followed by MTX on the fourth day is effective. Bacillus Calmette-Guérin scarification, while provoking measurable responses in vivo and in vitro, had no measurable, specific anti-tumour reaction, since no effect was observed on relapse rate, duration of remission or survival. High-dose CPM produces objective responses in patients previously resistant to conventional doses. Teniposide (VM 26) is currently undergoing phase 2 trial, and definite short-lived responses have been recorded.

Antineoplastic Combined Chemotherapy Protocols↗